Mobile Site ›

What the FDA Relabeling of Abacavir Means for You and Your Patient



Subscribe

Receive notification when new Hot Topics are published:

Clinical Utility3

Slide 13

November 2008

In patients who have clinically-suspected hypersensitivity reaction, the sensitivity approximately 46% and the specificity is about 98%. The negative predictive value is exceedingly high and is about 100%, where the absence of HLA-B*5701 correlates with absence of abacavir hypersensitivity reaction. The positive predictive value is approximately 61% and this correlates with individuals with the HLA-B*5701 allele who had a suspected hypersensitivity reaction with abacavir.

Immunologically-confirmed hypersensitivity reactions, however, show higher sensitivity and specificity. The negative predictive value is still 100% and the positive predictive value is about 48% with individuals who have the alleles and had a confirmed hypersensitivity reaction.

Clinical Utility3

 


Jump to section:


Key